These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 14695400)

  • 1. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings.
    Huppertz A; Balzer T; Blakeborough A; Breuer J; Giovagnoni A; Heinz-Peer G; Laniado M; Manfredi RM; Mathieu DG; Mueller D; Reimer P; Robinson PJ; Strotzer M; Taupitz M; Vogl TJ;
    Radiology; 2004 Jan; 230(1):266-75. PubMed ID: 14695400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study.
    Bluemke DA; Sahani D; Amendola M; Balzer T; Breuer J; Brown JJ; Casalino DD; Davis PL; Francis IR; Krinsky G; Lee FT; Lu D; Paulson EK; Schwartz LH; Siegelman ES; Small WC; Weber TM; Welber A; Shamsi K
    Radiology; 2005 Oct; 237(1):89-98. PubMed ID: 16126918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of Gd-BOPTA and Gd-DTPA in contrast-enhanced MR imaging of the liver].
    Zhang HM; Ouyang H; Zhou CW
    Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):111-5. PubMed ID: 16750014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection and characterization of focal hepatic tumors: a comparison of T2-weighted MR images before and after the administration of gadoxectic acid.
    Kim YK; Kwak HS; Kim CS; Han YM
    J Magn Reson Imaging; 2009 Aug; 30(2):437-43. PubMed ID: 19629973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.
    Ichikawa T; Saito K; Yoshioka N; Tanimoto A; Gokan T; Takehara Y; Kamura T; Gabata T; Murakami T; Ito K; Hirohashi S; Nishie A; Saito Y; Onaya H; Kuwatsuru R; Morimoto A; Ueda K; Kurauchi M; Breuer J
    Invest Radiol; 2010 Mar; 45(3):133-41. PubMed ID: 20098330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual contrast enhanced magnetic resonance imaging of the liver with superparamagnetic iron oxide followed by gadolinium for lesion detection and characterization.
    Kubaska S; Sahani DV; Saini S; Hahn PF; Halpern E
    Clin Radiol; 2001 May; 56(5):410-5. PubMed ID: 11384141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging.
    Schneider G; Altmeyer K; Kirchin MA; Seidel R; Grazioli L; Morana G; Saini S
    Invest Radiol; 2007 Feb; 42(2):105-15. PubMed ID: 17220728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinguishing hemangiomas from malignant solid hepatic lesions: a comparison of heavily T2-weighted images obtained before and after administration of gadoxetic acid.
    Ahn SJ; Kim MJ; Hong HS; Kim KA; Song HT
    J Magn Reson Imaging; 2011 Aug; 34(2):310-7. PubMed ID: 21598345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
    Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
    Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine-enhanced magnetic resonance imaging in five hundred seventy-two patients with known or suspected liver lesions: results of a multicenter, double-blind, interindividual, randomized clinical phase-III trial.
    Hammerstingl R; Adam G; Ayuso JR; Van Beers B; Belfiore G; Bellin MF; Bongartz G; Ernst O; Frericks B; Giuseppetti G; Heinz-Peer G; Laghi A; Martin J; Pering C; Reimer P; Richter GM; Roemer FW; Schäfer FK; Vilgrain V; Vogl TJ; Weishaupt D; Wall A; Zech CJ; Tombach B
    Invest Radiol; 2009 Mar; 44(3):168-76. PubMed ID: 19169143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging--a multicenter phase III clinical study.
    Petersein J; Spinazzi A; Giovagnoni A; Soyer P; Terrier F; Lencioni R; Bartolozzi C; Grazioli L; Chiesa A; Manfredi R; Marano P; Van Persijn Van Meerten EL; Bloem JL; Petre C; Marchal G; Greco A; McNamara MT; Heuck A; Reiser M; Laniado M; Claussen C; Daldrup HE; Rummeny E; Kirchin MA; Pirovano G; Hamm B
    Radiology; 2000 Jun; 215(3):727-36. PubMed ID: 10831691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine.
    Filippone A; Blakeborough A; Breuer J; Grazioli L; Gschwend S; Hammerstingl R; Heinz-Peer G; Kittner T; Laghi A; Leen E; Lencioni R; Lucidarme O; Remplik P; Robinson PJ; Ruehm SG; Schaefer F; Stoupis C; Tombach B; Valette PJ; Zech CJ; Huppertz A
    J Magn Reson Imaging; 2010 Feb; 31(2):356-64. PubMed ID: 20099349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can a multiphasic contrast-enhanced three-dimensional fast spoiled gradient-recalled echo sequence be sufficient for liver MR imaging?
    Coulam CH; Chan FP; Li KC
    AJR Am J Roentgenol; 2002 Feb; 178(2):335-41. PubMed ID: 11804888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal T2-weighted MR cholangiopancreatographic images can be obtained after administration of gadoxetic acid.
    Kim KA; Kim MJ; Park MS; Lim JS; Choi JY; Hong HS; Kim KW
    Radiology; 2010 Aug; 256(2):475-84. PubMed ID: 20656837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mangafodipir trisodium-enhanced MRI for the detection and characterization of focal hepatic lesions: is delayed imaging useful?
    Chung JJ; Kim MJ; Kim KW
    J Magn Reson Imaging; 2006 May; 23(5):706-11. PubMed ID: 16565954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection and characterization of small focal hepatic lesions (≤2.5 cm in diameter): a comparison of diffusion-weighted images before and after administration of gadoxetic acid disodium at 3.0T.
    Song KD; Kim YK; Lee WJ; Lee MW; Park MJ; Hwang J; Lee MH
    Acta Radiol; 2012 Jun; 53(5):485-93. PubMed ID: 22535883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.
    Knopp MV; Runge VM; Essig M; Hartman M; Jansen O; Kirchin MA; Moeller A; Seeberg AH; Lodemann KP
    Radiology; 2004 Jan; 230(1):55-64. PubMed ID: 14695387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of fast dynamic imaging and the use of Gd-EOB-DTPA for MR-guided liver interventions.
    Fischbach F; Thormann M; Seidensticker M; Kropf S; Pech M; Ricke J
    J Magn Reson Imaging; 2011 Oct; 34(4):874-9. PubMed ID: 21769983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection, classification, and characterization of focal liver lesions: Value of diffusion-weighted MR imaging, gadoxetic acid-enhanced MR imaging and the combination of both methods.
    Holzapfel K; Eiber MJ; Fingerle AA; Bruegel M; Rummeny EJ; Gaa J
    Abdom Imaging; 2012 Feb; 37(1):74-82. PubMed ID: 21597893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas.
    Yoon JH; Lee EJ; Cha SS; Han SS; Choi SJ; Juhn JR; Kim MH; Lee YJ; Park SJ
    J Vasc Interv Radiol; 2010 Mar; 21(3):348-56. PubMed ID: 20116285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.